scholarly article | Q13442814 |
P50 | author | Vishesh Paul | Q82787793 |
P2093 | author name string | Yizhak Kupfer | |
Nisarg Changawala | |||
Joost van Ginkel | |||
Edward Chapnick | |||
Sriharsha Rao | |||
Ceres Tiu | |||
Robbert Crusio | |||
P2860 | cites work | Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia | Q45086694 |
Clinical and economic consequences of ventilator-associated pneumonia. | Q45925029 | ||
Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. | Q45974680 | ||
Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. | Q46016195 | ||
Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan | Q46105767 | ||
Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group | Q21195082 | ||
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference | Q29618757 | ||
2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings | Q29619731 | ||
"Swimming in resistance": Co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosa | Q33648238 | ||
Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium | Q34429494 | ||
Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients | Q35065863 | ||
Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens | Q35867414 | ||
"Silent" dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast Ohio | Q36115511 | ||
Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? | Q36335694 | ||
Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections | Q37263364 | ||
Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy | Q37656243 | ||
Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies | Q37996299 | ||
Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City | Q39687830 | ||
In Vitro Evaluation of Antibiotic Synergy for Polymyxin B-Resistant Carbapenemase-Producing Klebsiella pneumoniae | Q41827843 | ||
Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates? | Q41963870 | ||
In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases | Q42031262 | ||
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. | Q42262051 | ||
In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases | Q42577530 | ||
Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program | Q43841688 | ||
Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases | Q44298896 | ||
A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections | Q44445854 | ||
Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria | Q44728336 | ||
P433 | issue | 1 | |
P921 | main subject | epidemiology | Q133805 |
carbapenem antibiotic | Q410897 | ||
P304 | page(s) | 1-8 | |
P577 | publication date | 2013-11-08 | |
P1433 | published in | Infectious Diseases | Q7429961 |
P1476 | title | Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy | |
P478 | volume | 46 |